Alira Health Advises Innovus Pharma in Licensing Agreement with Densmore Laboratorie

Paris, France – August 1, 2017-Innovus Pharma announced the signing of an exclusive license and distribution agreement with Densmore Pharmaceutical International for the commercialization of Zestra® in France and Belgium.

Zestra® is approved in Canada, the European Union, India, Hong Kong, United Arab Emirates, United Kingdom and Morocco.

“We are pleased to expand the commercialization market for Zestra® in the European Union to France and Belgium. Densmore is our fifteenth distribution partner for our products outside the United States and is very important for us to compete in one of the largest markets in Europe,” stated Dr. Bassam Damaj, CEO at Innovus Pharma. “This partnership brings us one step closer to achieving our 2017 corporate goals for revenue and profitability from our international distributors,” added Dr. Damaj.

“We are excited to commercialize Zestra® for the French and Belgian markets as it will fulfill a large unmet medical need. Zestra® is a very well-studied project with strong placebo controlled clinical trials. We believe it will provide a strong natural solution for women,” said Dr. Philippe Caron, CEO of Densmore Pharmaceutical International, and authority on women’s health products in the French market.

Alira Health acted as an advisor for Innovus Pharma.

ABOUT DENSMORE PHARMACEUTICAL

Densmore Pharmaceutical was founded in 1946 in Monaco, France. Its research and development center has about 70 years of expertise in vitamin therapy and micro-nutrition formulas. Since the early 2000’s, the laboratory has acquired new skills in drugs, medical devices and cosmetics. Densmore Pharmaceutical received two innovation and research awards for their entire range of products. In addition to its presence in France, the company expanded to many countries in Europe and North Africa. Densmore Pharmaceutical aims at making innovative products that combine safety, security and service available to all medical professions and patients to meet their health needs and well-being in everyday life.

ABOUT INNOVUS PHARMA

Headquartered in San Diego, Innovus Pharma is an emerging over-the-counter (OTC) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve people’s health, vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through their OTC medicines and consumer and health products, commercial partners to primary care physicians, urologists, gynecologists and therapists, and directly to consumers through on-line channels, retailers and wholesalers. The company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (ANDA) products. Innovus Pharma is actively pursuing opportunities where existing prescription drugs have recently – or are expected to – change from prescription (or Rx) to OTC.